A new study found that anti-rejection drugs following an organ transplant may explain patients' increased risk of developing cancer in the next decade, possibly due to increased production of vascular endothelial growth factor that could feed tumor growth. The Harvard researchers also found that targeted anti-VEGF therapy could help reduce the cancer risk.

Full Story:

Related Summaries